


EXHIBIT AAppendix of Amendments


12. (Four Times Amended) A pharmaceutical composition comprising an N-acyl derivative of a D- or L-tryptophanyl-ester for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases having the following formula:



wherein X is C(O)R₁, and R₁ is a saturated C₁-C₁₈ hydrocarbon residue and R₂ is a saturated or unsaturated C₂-C₁₈ hydrocarbon residue, and a pharmaceutically acceptable carrier[, alone or] in combination with a second therapeutic compound.

17. (Twice Amended) The pharmaceutical composition according to claim 12, wherein the N-acyl derivative[, is an N-acetyl derivative and]. is selected from the group consisting of N-dodecanoyl-tryptophanethyl-ester.

18. (Twice Amended) A pharmaceutical composition comprising an N-acyl derivative of a D- or L-tryptophanyl-ester, wherein the N-acyl derivative has the following formula:



wherein X is C(O)R₁, and R₁ is a saturated C₁-C₁₈ or unsaturated C₂-C₇ hydrocarbon residue and R₂ is a saturated or unsaturated C₉-C₁₈ hydrocarbon residue, and a pharmaceutically acceptable carrier in combination with a second therapeutic compound.

22. (Amended) The composition according to claim 12 or [21] 18, wherein the second therapeutic compound is for treating a degenerative disease or cancer.

23. (Twice Amended) The pharmaceutical composition according to claim 12 or [21] 18, wherein the second therapeutic compound is selected from the group consisting of ciliary neurotropic factor (CNTF), aniracetam, buflomedil, choline, co-dergocrine, cyclandelate, desferrioxamine, eptastigmine, fampridine, galantamine, isoxusuprine, [lecithin,] linopiridine, metriphosphate, naftidrofuryl, nicergoline, nicotine, nimodipine, oxiracetam, physostigmine, pilocarpine, piracetam, pramiracetam, propentofylline, pyritinol, RS-86, selegiline, suronacrine, tacrine, velnacrine, somatomedines, protirelin, and an immunoglobulin[and an immunosuppressive].

24. (Amended) The composition according to claim

[21] 18, wherein the degenerative disease is selected from the group consisting of Alzheimers' disease, Parkinson's disease, apoplectic fit and amyotrophic lateral sclerosis.

25. (Amended) The composition according to claim [21] 18, wherein the degenerative disease is Alzheimers' disease.

26. (Amended) The composition according to claim [21] 18, wherein the degenerative disease is Parkinson's disease.

27. (Amended) The composition according to claim [21] 18, wherein the degenerative disease is apoplectic fit.

28. (Amended) The composition according to claim [21] 18, wherein the degenerative disease is amyotrophic lateral sclerosis.